CGRP blockers

Biohaven, sporting new data, moves closer to CGRP finish line—and maybe M&A
Biohaven, sporting new data, moves closer to CGRP finish line—and maybe M&A
Fierce Pharma
Biohaven
migraines
CGRP blockers
rimegepant
Flag link:
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
Xconomy
migraines
CGRP blockers
Aimovig
Amgen
Ajovy
Teva Pharmaceutical
Emgality
Eli Lilly
Flag link:
Lilly claims fast FDA review for Emgality in cluster headache
Lilly claims fast FDA review for Emgality in cluster headache
Pharmaforum
Eli Lilly
migraines
CGRP blockers
Emgality
episodic cluster headache
Flag link:
Can Botox hang with CGRP in migraine? Allergan says yes; analysts are skeptical
Can Botox hang with CGRP in migraine? Allergan says yes; analysts are skeptical
Fierce Pharma
Allergan
Botox
migraines
CGRP blockers
Amgen
Novartis
Aimovig
Teva Pharmaceutical
Ajovy
Eli Lilly
Emgality
Flag link:
Don't fret about Lilly's 3rd-to-market start in CGRP, exec says. It's got big plans in migraine and pain, too
Don't fret about Lilly's 3rd-to-market start in CGRP, exec says. It's got big plans in migraine and pain, too
Fierce Pharma
Eli Lilly
Emgality
migraines
CGRP blockers
Flag link:
Teva calls off CGRP drug discovery and development pact, returns preclinical asset to Sosei
Teva calls off CGRP drug discovery and development pact, returns preclinical asset to Sosei
Endpoints
Teva Pharmaceutical
CGRP blockers
R&D
drug development
Heptares Therapeutics
Flag link:
In latest blow to Teva, CGRP migraine med delayed while rivals race towards the finish line
In latest blow to Teva, CGRP migraine med delayed while rivals race towards the finish line
Endpoints
Teva Pharmaceutical
migraines
CGRP blockers
fremanezumab
Flag link:
Amgen pulls ahead in sprint towards CGRP approval with promising PhIII migraine data
Amgen pulls ahead in sprint towards CGRP approval with promising PhIII migraine data
Endpoints
Amgen
CGRP blockers
migraines
Aimovig
erenumab
Flag link:
Amgen And Novartis: First Mover Advantage Is A Must
Amgen And Novartis: First Mover Advantage Is A Must
Seeking Alpha
Amgen
Novartis
migraines
erenumab
CGRP blockers
Flag link:
With late-stage data in on the CGRP migraine drug erenumab, Novartis and Amgen rework commercialization pact
With late-stage data in on the CGRP migraine drug erenumab, Novartis and Amgen rework commercialization pact
Endpoints
Novartis
Amgen
CGRP blockers
migraines
erenumab
Flag link:
Novartis, Amgen rack up their first PhIII success in a crowded CGRP migraine drug field
Novartis, Amgen rack up their first PhIII success in a crowded CGRP migraine drug field
Endpoints
Novartis
Amgen
CGRP blockers
migraines
erenumab
Flag link:
The drug industry might finally have an answer for migraines
The drug industry might finally have an answer for migraines
Stat
migraines
Amgen
Eli Lilly
Alder Biopharma
Teva Pharmaceutical
CGRP blockers
Flag link: